Saturday 17 October 2026
Export LIVN’s income statement to Excel — free account
LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
77.60
0.90
−1.15%
Follow LIVN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 4 | 2 | 6 | 6 | 5 | 7 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 157.94 | 39.92 | 0.00 |
Altman Z-Score |
2.76 | 4.09 | 2.54 | 2.13 | 1.26 | 2.82 | 1.68 | 1.60 | 1.79 | 1.74 |
P/S ratio |
2.30 | 3.80 | 4.01 | 3.36 | 3.44 | 4.28 | 2.89 | 2.36 | 2.00 | 2.42 |
Altman Z″-Score (non-manufacturers) |
4.19 | 4.19 | 0.63 | 0.49 | 0.19 | 0.11 | 1.23 | 1.44 | 2.26 | 0.72 |
P/FCF ratio |
48.29 | 65.95 | 46.43 | 0.00 | 0.00 | 60.06 | 73.68 | 72.24 | 18.93 | 18.94 |
P/Operating CF |
54.27 | 217.84 | 212.35 | 1,272.49 | 86.99 | 132.22 | 157.79 | 50.52 | 31.91 | 40.73 |
Beneish M-Score |
— | (2.32) | (3.12) | (2.77) | (3.36) | (2.93) | (2.95) | (2.35) | (2.82) | (3.30) |
P/B ratio |
1.30 | 2.12 | 2.95 | 2.64 | 2.90 | 3.42 | 2.44 | 2.13 | 1.90 | 2.80 |
Price to Tangible BV |
3.86 | 7.77 | 0.00 | 0.00 | 0.00 | 0.00 | 41.99 | 11.67 | 7.54 | 18.94 |
EV/Sales |
2.38 | 3.86 | 4.12 | 3.62 | 3.87 | 4.31 | 2.91 | 2.37 | 1.93 | 2.23 |
EV/EBITDA |
14.09 | 18.48 | 0.00 | 0.00 | 0.00 | 53.16 | 22.59 | 239.67 | 11.97 | 10.98 |
EV/Operating CF |
25.48 | 42.73 | 37.82 | (43.05) | (45.58) | 43.48 | 42.58 | 36.51 | 13.20 | 12.18 |
EV/FCF |
50.10 | 66.85 | 47.70 | (32.92) | (30.73) | 60.48 | 74.33 | 72.48 | 18.21 | 17.48 |
Quick Ratio |
0.72 | 0.93 | 0.61 | 0.62 | 1.41 | 0.56 | 2.35 | 2.37 | 2.34 | 1.05 |
Current Ratio |
2.32 | 2.14 | 1.07 | 1.07 | 2.29 | 0.97 | 2.98 | 2.95 | 2.87 | 1.36 |
Net Debt/EBITDA |
0.51 | 0.25 | (0.74) | (6.29) | (2.49) | 0.38 | 0.20 | 0.77 | (0.48) | (0.92) |
Debt/Assets |
5.24% | 5.83% | 6.60% | 14.00% | 27.32% | 10.88% | 23.60% | 24.15% | 25.04% | 14.45% |
Debt/Equity |
0.07 | 0.08 | 0.11 | 0.24 | 0.59 | 0.19 | 0.45 | 0.46 | 0.48 | 0.31 |
Asset Turnover |
0.39 | 0.42 | 0.44 | 0.44 | 0.39 | 0.45 | 0.45 | 0.49 | 0.51 | 0.54 |
Operating CF/Net income |
(1.44) | (3.64) | (0.64) | 0.58 | 0.23 | (0.75) | (0.81) | 4.27 | 2.89 | (1.05) |
Capex/Depreciation |
(0.29) | (0.25) | (0.28) | (0.22) | (0.31) | (0.30) | (0.13) | (0.42) | (0.65) | (0.89) |
Interest Coverage |
3.15 | 12.37 | (25.25) | (11.37) | (6.71) | (0.02) | (1.59) | (1.16) | 2.05 | 4.05 |
| (3.57%) | (1.42%) | (11.41%) | (10.92%) | (27.98%) | (11.30%) | (6.89%) | 1.41% | 4.87% | (19.24%) | |
| (2.56%) | (1.04%) | (7.50%) | (6.35%) | (14.50%) | (5.90%) | (3.84%) | 0.74% | 2.56% | (9.49%) | |
ROIC |
1.17% | 3.23% | (9.54%) | (6.46%) | (11.32%) | (0.04%) | (3.89%) | (3.33%) | 6.59% | 13.24% |
Return on Tangible Assets |
(9.42%) | (3.82%) | (83.09%) | (72.23%) | (61.98%) | (102.68%) | (11.72%) | 2.17% | 6.98% | (45.22%) |
Average Days of Receivables |
80.67 | 101.73 | 84.46 | 86.78 | 72.03 | 65.34 | 65.41 | 68.05 | 56.25 | 56.80 |
Research and Development Expense of Revenue |
8.51% | 10.82% | 13.18% | 13.54% | 16.37% | 17.71% | 15.25% | 16.80% | 14.56% | 13.38% |
Selling, General and Administrative Expense of Revenue |
36.81% | 37.55% | 42.00% | 48.74% | 47.80% | 45.58% | 45.92% | 43.58% | 40.60% | 39.54% |
Intangible Assets out of Total Assets |
0.48 | 0.53 | 0.68 | 0.63 | 0.57 | 0.59 | 0.50 | 0.43 | 0.39 | 0.39 |
Share Based Compensation of Revenue |
2.03% | 1.88% | 2.43% | 3.00% | 3.76% | 3.92% | 4.39% | 3.15% | 2.71% | 2.61% |
Graham Net Nets |
0.08 | 0.05 | (0.12) | (0.13) | (0.18) | (0.05) | (0.07) | (0.06) | (0.02) | (0.09) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.06 | 25.21 | 0.00 |
Earnings Yield |
(2.85%) | (0.65%) | (4.27%) | (4.26%) | (10.69%) | (3.04%) | (2.92%) | 0.63% | 2.50% | (7.23%) |
Free Cash Flow Yield |
2.07% | 1.52% | 2.15% | (3.27%) | (3.66%) | 1.67% | 1.36% | 1.38% | 5.28% | 5.28% |
Revenue per Share |
19.75 | 21.02 | 22.83 | 22.42 | 19.23 | 20.45 | 19.11 | 21.39 | 23.11 | 25.45 |
Operating CF per Share |
1.85 | 1.90 | 2.48 | (1.89) | (1.63) | 2.03 | 1.31 | 1.39 | 3.37 | 4.66 |
Capex per Share |
(0.76) | (0.58) | (0.49) | (0.58) | (0.72) | (0.50) | (0.50) | (0.63) | (0.87) | (1.35) |
Free Cash Flow per Share |
1.08 | 1.31 | 1.99 | (2.46) | (2.36) | 1.52 | 0.81 | 0.76 | 2.51 | 3.31 |
Cash per Share |
0.81 | 1.94 | 0.97 | 1.26 | 5.20 | 4.11 | 9.64 | 10.71 | 13.34 | 11.65 |
Shareholders Equity per Share |
34.93 | 37.70 | 31.01 | 28.62 | 22.83 | 25.57 | 22.58 | 23.69 | 24.34 | 22.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
34.93 | 37.70 | 31.01 | 28.62 | 22.83 | 25.57 | 22.58 | 23.69 | 24.34 | 22.00 |
Free Cash Flow |
52.93 | 63.17 | 96.71 | (119.12) | (114.45) | 77.07 | 43.40 | 41.09 | 136.02 | 180.57 |
Working Capital |
462.80 | 463.84 | 36.55 | 36.89 | 398.99 | (17.79) | 588.74 | 653.18 | 735.06 | 293.54 |
Capital Expenditures |
(37.22) | (28.17) | (23.78) | (27.98) | (35.02) | (25.48) | (26.52) | (33.83) | (47.02) | (73.77) |
Net Current Asset Value |
176.97 | 181.28 | (512.67) | (478.64) | (582.65) | (227.12) | (201.01) | (163.78) | (58.94) | (304.45) |
EV/EBIT |
68.69 | 40.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.72 | 15.53 |
Capex to Sales |
0.04 | 0.03 | 0.02 | 0.03 | 0.04 | 0.02 | 0.03 | 0.03 | 0.04 | 0.05 |
Price to Operating Income |
66.20 | 39.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.46 | 16.83 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.64 | 0.60 | 0.44 | 0.70 | 0.69 | 0.56 | 1.42 | 0.52 | 0.43 | 0.34 |
Cash ROIC |
2.83% | 3.07% | 5.63% | (6.68%) | (5.67%) | 4.42% | 1.92% | 1.68% | 5.09% | 8.16% |
Accounts Receivable Turnover |
3.97 | 4.09 | 4.11 | 4.22 | 4.23 | 5.60 | 5.55 | 5.79 | 6.14 | 6.79 |
Accounts Payable Turnover |
4.47 | 4.57 | 4.57 | 4.43 | 4.26 | 4.65 | 4.42 | 5.13 | 5.31 | 5.37 |
Inventory Turnover |
2.35 | 2.60 | 2.50 | 2.27 | 2.43 | 2.98 | 2.67 | 2.87 | 2.71 | 2.87 |
Average Days of Payables |
64.77 | 87.00 | 75.29 | 87.00 | 79.21 | 75.36 | 86.22 | 74.19 | 63.63 | 79.12 |
Days of Inventory on Hand |
119.77 | 146.30 | 150.65 | 166.27 | 123.95 | 117.29 | 150.12 | 135.72 | 134.67 | 134.13 |
Average Receivables |
242.80 | 247.70 | 269.14 | 256.95 | 221.06 | 184.86 | 184.23 | 199.09 | 204.12 | 204.57 |
Average Payables |
90.76 | 78.92 | 81.33 | 81.31 | 79.78 | 70.83 | 71.16 | 77.58 | 75.29 | 83.44 |
Average Inventory |
172.73 | 138.74 | 149.00 | 158.84 | 139.72 | 110.56 | 117.61 | 138.63 | 147.73 | 156.13 |
Average Assets |
2,450.69 | 2,423.26 | 2,526.80 | 2,480.75 | 2,405.88 | 2,300.46 | 2,247.86 | 2,362.17 | 2,467.98 | 2,556.22 |
Average Common Equity |
1,759.19 | 1,761.11 | 1,659.53 | 1,443.73 | 1,246.49 | 1,201.96 | 1,251.13 | 1,242.63 | 1,298.94 | 1,260.12 |
Columns are period end dates